📰 Confidence Interval News
Page 26 - Confidence Interval News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Confidence Interval. Real-time updates on events, politics, business and more.
June 9, 2023
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and the Blood and Marrow Transplant Clinical Trials Network (BMT...
June 9, 2023
Data from two studies continue to show the long-term efficacy and safety of fixed-duration venetoclax combination regimens across different lines of therapy in...
June 8, 2023
1. In this randomized controlled trial, emodepside had higher efficacy in treating Trichuris trichiura infections than albendazole and placebo. 2. A higher dose of emodepside was required for those with hookworm infections compared to those with T. trichiura infections. Evidence Rating Level: 1 (Excellent) Study Rundown: T. trichiura and hookworm are intestinal helminths that are transmitted
June 8, 2023
1. In this retrospective study of Medicare claims data from 2016 to 2019, receipt of opioid use disorder (OUD) medications (buprenorphine and naloxone) was lower among Black and Hispanic patients than White patients after OUD-related adverse events. 2. Analysis of available methadone receipt data from 2020 to 2021 showed that Black patients received either buprenorphine
June 6, 2023
1. In this open-label randomized trial, percutaneous tricuspid transcatheter edge-to-edge repair (TEER) reduced severe tricuspid regurgitation and improved quality of life compared to diuretic therapy. 2. Major adverse events related to the TEER procedure occurred in less than 2% of patients in the group. Evidence Rating Level: 1 (Excellent) Study Rundown: The standard treatment for
June 5, 2023
News Release Media Contact: Christie Corbett +1 857-636-0211 Satu Glawe +49 172-294-6264 ... | June 5, 2023
June 5, 2023
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that results from the Phase 3 CARTITUDE-4 study showed CARVYKTI®...
June 5, 2023
News Release Media Contacts: Jessica Castles Smith +1 732-501-8181 Satu Glawe +49 172-294-6264 ... | June 5, 2023
June 5, 2023
At 16 months median follow-up, cilta-cel significantly improved progression-free survival compared to two standard of care treatment regimens1 ...
June 5, 2023
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today long-term data from the pivotal Phase 1/2 MajesTEC-1 study showing...